RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -27.13% | -28.92% | 0.47% | -11.57% | -11.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.13% | -28.92% | 0.47% | -11.57% | -11.53% |
| Cost of Revenue | 49.94% | -12.45% | 6.11% | -73.20% | -41.45% |
| Gross Profit | -99.93% | -62.15% | -15.46% | 173.41% | 70.89% |
| SG&A Expenses | -42.30% | -56.29% | -20.39% | 191.54% | -3.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -26.67% | -21.21% | -43.08% | -8.10% | -56.73% |
| Total Operating Expenses | -17.92% | -44.65% | -12.79% | 52.95% | -17.67% |
| Operating Income | 6.98% | 54.85% | 21.37% | -82.04% | 23.93% |
| Income Before Tax | 47.54% | 93.75% | 53.91% | -196.95% | 6.81% |
| Income Tax Expenses | -- | -- | -- | -16.90% | -- |
| Earnings from Continuing Operations | 47.54% | 88.58% | 57.61% | -196.40% | 6.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.54% | 88.58% | 57.61% | -196.40% | 6.81% |
| EBIT | 6.98% | 54.85% | 21.37% | -82.04% | 23.93% |
| EBITDA | -14.19% | 56.92% | 15.59% | -84.91% | 27.43% |
| EPS Basic | 47.54% | 88.79% | 57.75% | -195.80% | 6.15% |
| Normalized Basic EPS | 44.74% | 65.67% | 31.67% | -67.29% | 5.00% |
| EPS Diluted | 47.54% | 88.79% | 57.75% | -195.80% | 6.15% |
| Normalized Diluted EPS | 44.74% | 65.67% | 31.67% | -67.29% | 5.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.02% | -1.07% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.02% | -1.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |